SH 08 - Hematologic Malignancies - Science Highlights

session DESCRIPTION

The following abstracts will be highlighted in this session:

• 4 — Decreasing the Dose of Consolidation Radiation Therapy in DLBCL/HGBL: A Phase II Trial by the International Lymphoma Radiation Oncology Group — Christopher Kelsey
• 330 — Pembrolizumab and Involved Site Radiation Therapy Alone as an Alternative to Transplant in Patients with Localized Failure following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study — Alexandra Dreyfuss
• 1101 — Consensus Organ at Risk (OAR) Constraints for Radiotherapy (RT) for Hematologic Malignancies for NCTN Trials — Austin Sim
• 331 — Prospective Study of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cells for Relapsed/Refractory B-Cell Lymphomas — Brandon Imber
• 329 — Phase II Trial of 'Re-Priming' Radiation Therapy for Relapsed/Refractory Non-Hodgkin Lymphoma Patients in Incomplete Response after Chimeric Antigen Receptor T-cell (CAR-T) Therapy — Kiran Kumar